Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Real-World Outcomes with Complement Inhibitors for Geographic Atrophy: A Comparative Study of Pegacetacoplan versus Avacincaptad Pegol

1 Mar 2025

Abstract excerpt

Purpose: To compare real-world outcomes in subjects who underwent treatment with intravitreal avacincaptad pegol (IVA) or intravitreal pegacetacoplan (IVP) for geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Methods: This study was undertaken as a retrospective, comparative assessment of subjects who underwent IVA or IVP treatment for GA secondary to AMD at two community-based...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Ophthalmology and Visual Impairment Studies
Share to Retinal Diseases and Treatments
Share to Retinopathy of Prematurity Studies

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 40191000
DOI: 10.2147/opth.s518398

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Real-World Outcomes with Complement Inhibitors for Geographic Atrophy: A Comparative Study of Pegacetacoplan versus Avacincaptad PegolPMID 40191000Read ↗

COMPLEMENT INHIBITION FOR GEOGRAPHIC ATROPHYSemantic proximity Read ↗

Complement C3 Inhibitor Pegcetacoplan for Geographic Atrophy Secondary to Age-Related Macular DegenerationSemantic proximity Read ↗

Treating patients with geographic atrophy: are we there yet?Semantic proximity Read ↗

Local Complement Inhibition for Geographic Atrophy in Age-Related Macular Degeneration: Prospects, Challenges, and Unanswered QuestionsSemantic proximity Read ↗

Informing Endpoints for Clinical Trials of Geographic AtrophySemantic proximity Read ↗

The roadmap to geographic atrophy treatment: A journey of trials and promiseSemantic proximity Read ↗

Ocular biomarker profiling after complement factor I gene therapy in geographic atrophy secondary to age-related macular degenerationSemantic proximity Read ↗

Systemic complement inhibition with eculizumab for geographic atrophy in age-related macular degeneration: the COMPLETE study.Semantic proximity Read ↗

Complement system modulation in age-related macular degeneration: navigating failures, building future successesSemantic proximity Read ↗

Complement cascade inhibition in geographic atrophy: a review.Semantic proximity Read ↗

Incidence and progression of geographic atrophy: observations from a population-based cohort.Semantic proximity Read ↗

Therapeutic Approaches with Intravitreal Injections in Geographic Atrophy Secondary to Age-Related Macular Degeneration: Current Drugs and Potential MoleculesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.